Genalyte, Inc., a San Diego, CA-based biotech company, raised an additional $36m in its latest financing round.
The round was led by Khosla Ventures and Redmile Group.
The company intends to use the funds to continue to develop the platform and to prove performance through additional clinical studies.
Led by founder and CEO Cary Gunn, Genalyte provides the Maverick™ Detection System, a testing platform which leverages microchip technology containing arrays of photonic microring sensors to simultaneously analyze multiple proteins/biomarkers from minimal sample volume.
The technology – usable inside physician offices by offering laboratory test results in under 15 minutes – is already in use commercially in the pharmaceutical industry.